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de Salud Carlos III, Madrid, SpainAbstractWe aimed to develop a simple prediction score to identify ﬂuconazole non-susceptible (Flu-NS) candidaemia using simple clinical criteria. A
derivation cohort was extracted from the CANDIPOP study, a prospective, multicentre, population-based surveillance programme on
candidaemia conducted in 29 hospitals in Spain from April 2010 to May 2011. The score was validated with an external, multicentre
cohort of adults with candidaemia in six tertiary hospitals in three countries. The prediction score was based on three variables selected
by a logistic regression model together with the severity of disease. In total, 617 and 297 cases of candidaemia were included in the
derivation and validation cohorts, respectively; of these, 134 (21.7%) and 57 (19.2%) were caused by Flu-NS strains. Factors
independently associated with Flu-NS were transplant recipient status (adjusted odds ratio (AOR) 2.13; 95% CI 1.01–4.55; p 0.047),
hospitalization in a unit with a high prevalence (15%) of Flu-NS strains (7.53; 4.68–12.10; p < 0.001), and previous azole therapy for at
least 3 days (2.04; 1.16–3.62; p 0.014). The area under the receiver operating characteristics curve (AUC) was 0.76 (0.72–0.81), and
using 2 points as the Flu-NS prediction score cut-off gave a sensitivity of 82.1%, a speciﬁcity of 65.6%, and a negative predictive value of
93%. The AUC in the validation cohort was 0.72 (95% CI 0.65–0.79). Hence, the Flu-NS prediction score helped to exclude Flu-NS
Candida strains. This could improve the selection of empirical treatments for candidaemia in the future.
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p://dx.doi.org/10.1016/j.cmi.2015.02.029IntroductionCandidaemia remains a frequent cause of nosocomial blood-
stream infection worldwide and is associated with signiﬁcant
morbidity, prolonged hospital stays, increased healthcare costs
and high mortality [1,2].
The empirical treatment of this life-threatening infection also
remains a challenge for clinicians. Although ﬂuconazole hasious Diseases. Published by Elsevier Ltd. All rights reserved
CMI Cuervo et al. Predicting ﬂuconazole non-susceptible candidaemia 684.e2typically been the preferred initial treatment, especially in
haemodynamically stable patients without previous azole
exposure [3,4], recent epidemiological studies raise concerns
about the increasing prevalence of Candida species non-
susceptible to ﬂuconazole (Flu-NS) [1,5]. Accordingly, current
guidelines have relegated ﬂuconazole to be used only as a step-
down treatment option [6,7]. However, some observational
studies suggest that this management strategy could have an as-
yet unknown ecological impact [8–10], in addition to the
obvious rise in healthcare expenses. It has therefore become
necessary to determine the current role of ﬂuconazole in the
empirical treatment of candidaemia.
We aimed to develop and validate a Flu-NS prediction score
that would be easy to use at the bedside, using only simple
clinical criteria to assess the risk factors for Flu-NS candidae-
mia. Ultimately, this tool could be useful when selecting an
empirical antifungal treatment for patients with candidaemia.Materials and methodsStudy design, setting and patients
We extracted a derivation cohort from the CANDIPOP study
(the Prospective Population Study on Candidaemia in Spain), a
prospective, multicentre, population-based surveillance pro-
gramme on candidaemia conducted in 29 hospitals in ﬁve of the
largest metropolitan areas of Spain [11]. Between April 2010
and May 2011, blood cultures positive for Candida spp. were
identiﬁed in the microbiology laboratories of participating
hospitals and reported to regional study collaborators who
collected clinical data using a standardized case report form as
described elsewhere [11]. The study was approved by the
ethics committees of each participating institution.
We created an external validation cohort that included all
adult patients diagnosed with candidaemia between January
2005 and December 2012 in six tertiary hospitals in three
countries (three in Spain, two in Argentina and one in Brazil).
Information was retrospectively collected by detailed review
of the medical records. The study was approved by the ethics
committees of the participating institutions. The same inclu-
sion and exclusion criteria were used as for the CANDIPOP
study.
Variables and deﬁnitions
The primary outcome variable was the presence of a Candida
bloodstream infection caused by a Flu-NS isolate. For the
purpose of this study, Candida strains were divided in two
groups according to MIC values obtained by CLSI procedure:
isolates fully susceptible to ﬂuconazole (Flu-S; i.e. those with an
MIC <4 mg/L) and isolates non-susceptible to ﬂuconazole (Flu-Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and InNS; i.e. those with an MIC 4 mg/L in addition to Candida
krusei, Candida glabrata and Candida guilliermondii regardless of
their MIC value), which included ﬂuconazole-resistant as well as
ﬂuconazole dose-dependently susceptible isolates. The MIC
cut-off value was selected according to CLSI criteria for Candida
species-speciﬁc clinical breakpoints [12]. For species in which
breakpoints are lacking, we considered as Flu NS the non-wild-
type isolates. We recorded only nine cases of candidaemia
caused by C. guilliermondii in the derivation cohort. Among
them, more than 66% (6/9) displayed a MIC of ﬂuconazole
4 mg/L. Nevertheless, we truly believe that these isolates
should be classiﬁed as Flu-NS, as there is scarce evidence that
C. guilliermondii is a good target for therapy with ﬂuconazole. As
the aim of the score is to provide a tool to safely choose an
empirical treatment, we are persuaded that it was a cautious
approach. For those episodes in which two different Candida
spp. were recovered simultaneously in the blood culture, at
least one strain was required to meet the criteria for Flu-NS. In
a second analysis in the derivation cohort, we used the deﬁni-
tion of Flu-S and Flu-NS strains according to the non-species-




Previous exposure to azoles was considered if it had
occurred in the 30 days before drawing the ﬁrst positive blood
culture. The type, dose and duration of previous antifungal
therapy were recorded. Severity of candidaemia was classiﬁed
as sepsis, severe sepsis, or septic shock at presentation ac-
cording to standard deﬁnitions [14]. To account for local
epidemiology and antifungal resistance patterns, we used a
variable that reﬂected resistance rates at the ward level in each
hospital. Wards with a prevalence of Flu-NS isolates >15%
were deﬁned as high prevalence units (HPU).
Microbiological studies
Candida isolates corresponding to episodes recorded in the
derivation cohort were processed and stored at participating
hospitals as described elsewhere [13]. Fluconazole susceptibility
testing was performed according to the CLSI M27-A3 [15] and
EUCAST (E.Def7.1 and E.Def7.2) [16,17] broth microdilution
methods. The ﬂuconazole MIC was deﬁned as the lowest drug
concentration that inhibited 50% of growth compared with the
growth control after 24 h of incubation at 35°C for all Candida
species, except for C. glabrata, which was determined after 48 h
to prevent misclassiﬁcation bias among the isolates [18]. CLSI
and EUCAST procedures were carried out at the Clinical
Microbiology Department of Gregorio Marañón Hospital and at
the Spanish National Centre for Microbiology in Madrid,
respectively, as previously reported [13].fectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 684.e1–684.e9
TABLE 1. Demographic, clinical and microbiological






cohort (n [ 297)
Demographics
Male sex, n (%) 367 (59.5) 174 (58.6)
Age (years), median (IQR) 67.8 (54.3–77.3) 62 (50–73.5)
Length of in-hospital stay (days),
median (IQR)
20 (12–36) 15 (3–30)
High prevalence unit, n (%) 269 (43.6) 169 (56.9)
Comorbidities, n (%)
Diabetes mellitus 153 (24.8) 89 (30)
Liver disease 95 (15.4) 58 (19.5)
COPD 74 (12) 69 (23.2)
Chronic renal disease 174 (28.2) 82 (27.6)
Dialysis 42 (6.8) 24 (8.1)
Cerebrovascular disease 50 (8.1) 40 (13.5)
Active malignancy 238 (38.6) 132 (44.4)
Transplant recipienta 40 (6.5) 44 (14.8)
HIV infection 16 (2.6) 13 (4.4)
Risk factors for candidaemia, n (%)
ICU admission (at onset) 173 (28) 77 (25.9)
Central venous catheter 459 (74.6) 178 (59.9)
Total parenteral nutrition 281 (45.5) 127 (42.8)
Previous gastrointestinal surgeryb 184 (29.8) 77 (25.9)
Neutropenia (<500) 26 (4.2) 30 (10.1)
Chemotherapyb 55 (8.9) 57 (19.2)
Corticosteroid therapyb 175 (28.4) 133 (44.8)
Previous antibioticsb 471 (76.4) 260 (87.5)
Previous antifungalsb 100 (16.2) 22 (7.4)
Previous azole therapy (3 days) b 78 (12.6) 15 (5.1)
Severity, n (%)
Septic shock 94 (15.2) 85 (28.6)
Source of infection, n (%)
Primary 342 (55.4) 142 (47.8)
Catheter-related 206 (33.4) 57 (19.1)
Urological 38 (6.2) 26 (8.8)
Abdominal 25 (4.1) 21 (7.1)
Other 6 (1) 3 (1)
Microbiology
Candida species, n (%)c
C. albicans 291 (46.3) 141 (47.5)
C. parapsilosis 136 (21.7) 49 (16.5)
C. glabrata 97 (15.4) 37 (12.5)
684.e3 Clinical Microbiology and Infection, Volume 21 Number 7, July 2015 CMIFor episodes recorded in the validation cohort, yeast iden-
tiﬁcation and in vitro antifungal activity were assessed at
participating hospitals using local routine methods. In vitro
antifungal activity was studied by a commercial microdilution
method (YeastOne®Sensitre®, TREK Diagnostic Systems Ltd,
East Grinstead, UK) or by E-test (BioMérieux SA, Paris,
France), in accordance with the manufacturer’s instructions.
Antifungal susceptibility of the isolates was classiﬁed according
to the CLSI M27-A3 document [15].
Statistical analysis
Categorical variables were compared using the chi-square or
Fisher exact tests; continuous variables were compared using
the Student’s t-test or Mann–Whitney U-test, as appropriate.
All statistical tests were two-tailed, and signiﬁcance was set at
p < 0.05.
Potential predictors of Flu-NS isolates were identiﬁed by
logistic regression analysis using the CLSI MIC clinical break-
points. To facilitate score generation and application in clinical
settings, continuous variables (e.g. days of previous azole
exposure) were transformed into binary factors using the most
discriminatory cut-off point. Statistically signiﬁcant variables in
univariate analysis were entered into a multivariate logistic
regression model. Calibration of the model was assessed by the
Hosmer–Lemeshow test. The ﬁnal regression model was
transformed into a point-based score to build the predictive
score. The logistic regression coefﬁcients for statistically sig-
niﬁcant predictors of Flu-NS isolates were rounded to integers
to assign the value of each variable. It was decided a priori that
septic shock would remain in the predictive score because it is
usually taken into account when choosing empirical therapy
using existing guidance [3].
The discriminatory power of the developed score was
evaluated by the area under the receiver operating character-
istics (ROC) curve (AUC) and the 95% CI. We selected the
best cut-off value to estimate the diagnostic sensitivity and
speciﬁcity in the validation set. The prediction score was
internally assessed with the MIC values obtained by the
EUCAST method in the CANDIPOP study and then applied to
the external validation cohort. The discrimination ability of the
score was again assessed by AUC of ROC curve analysis. Sta-
tistical analyses were performed with MICROSOFT SPSS-PC+,
version 15.0 (SPSS, Chicago, IL, USA).
C. tropicalis 52 (8.3) 40 (13.5)
C. krusei 14 (2.2) 13 (4.4)
Other 38 (6.1) 17 (5.7)
Flu-NS strains, n (%) 134 (21.7) 57 (19.2)Results
Abbreviations: COPD, chronic obstructive pulmonary disease; HIV, human
immunodeﬁciency virus; ICU, intensive care unit; IQR, interquartile range.
aThirteen haematopoietic stem cell transplants and 27 solid organ transplants in the
derivation cohort versus 17 and 27, respectively, in the validation cohort.
bWithin the preceding month.
cEleven cases of mixed candidaemia in the derivation cohort.Study population
In total, 773 episodes of candidaemia were documented in the
CANDIPOP study. Of these, we excluded patients whoClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectdeclined to participate (n = 21), those with more than one
episode (n = 23), and those <16 years old (n = 112). Conse-
quently, 617 cases of candidaemia were enrolled in the deri-
vation cohort. A total of 297 cases were analysed in the
validation cohort. Table 1 shows the baseline characteristics of
patients included in both the derivation and validation cohorts.
The most frequent species isolated in both cohorts was Candida
albicans. Flu-NS accounted for 134 strains isolated in the deri-
vation cohort (21.7%) compared with 57 strains isolated in the
validation cohort (19.2%).
Score derivation
The epidemiological and clinical characteristics of the patients
with Flu-S and with Flu-NS strains in the derivation cohort areious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 684.e1–684.e9
TABLE 3. Independent risk factors associated with Flu-NS
candidaemia: multivariate analysis
Characteristic AOR 95% CI p-value
Malignancy 1.27 0.82–1.96 0.282
Solid organ or haematopoietic
stem cell transplant recipient
2.13 1.01–4.55 0.047




Abbreviations: AOR, adjusted odds ratio; Flu-NS, isolates non-susceptible to
ﬂuconazole (i.e. those with an MIC 4 mg/L plus Candida krusei, Candida glabrata
and Candida guilliermondii, regardless of their MIC value).
aWithin the preceding month.
CMI Cuervo et al. Predicting ﬂuconazole non-susceptible candidaemia 684.e4compared in Table 2. Univariate analysis identiﬁed four vari-
ables that were signiﬁcantly associated with Flu-NS, including
epidemiological factors (HPU 80.6% versus 33.3% p < 0.001),
co-morbidities (malignancy: 47% versus 36.3%, p 0.024; or
previous solid organ or haematopoietic stem cell trans-
plantation: 13.4% versus 4.6%, p  0.001) and previous anti-
fungal therapy (azole therapy for at least 3 days in the previous
month 23.1 versus 9.7%, p < 0.001). The results are equivalent
for patients who received previous ﬂuconazole therapy during
>7 days or >14 days. Multivariate analysis summarized in
Table 3 shows that the independent factors associated with Flu-
NS were as follows: being a previous solid organ or haemato-
poietic stem cell transplantation recipient, hospitalization in an
HPU, and azole therapy for 3 days. Hosmer–Lemeshov
goodness-of-ﬁt of the ﬁnal model was 82%.TABLE 2. Univariate analysis of patients with Flu-NS and Flu-S




(n [ 134) p-value
Demographics
Male sex, n (%) 289 (59.8) 78 (58.2) 0.735
Age (years), median (IQR) 67.4 (54.2–76.8) 69.3 (55.5–77.7) 0.490
Length of in-hospital stay (days),
median (IQR)
20 (12–37.5) 21 (8.5–34) 0.146
High prevalence unit, n (%) 161 (33.3) 108 (80.6) <0.001
Comorbidities, n (%)
Diabetes mellitus 117 (24.2) 36 (26.9) 0.531
Liver disease 68 (14.1) 27 (20.1) 0.085
COPD 53 (11) 21 (15.7) 0.139
Chronic renal disease 143 (29.6) 31 (23.1) 0.141
Dialysis 35 (7.2) 7 (5.2) 0.411
Cerebrovascular disease 40 (8.3) 10 (7.5) 0.759
Active malignancy 175 (36.3) 63 (47) 0.024
Solid organ or haematopoietic stem
cell transplant recipient
22 (4.6) 18 (13.4) <0.001
HIV infection 10 (2.1) 6 (4.5) 0.121
Risk factors for candidaemia, n (%)
ICU admission (at onset) 141 (29.1) 32 (23.9) 0.578
Central venous catheter 364 (75.4) 95 (71.4) 0.337
Total parenteral nutrition 220 (45.5) 61 (45.5) 0.996
Previous gastrointestinal surgerya 145 (30) 39 (29.1) 0.837
Neutropenia (<500) 18 (3.7) 8 (6) 0.253
Chemotherapya 39 (8.1) 16 (11.9) 0.164
Corticosteroid therapya 137 (28.4) 38 (28.4) 0.999
Previous antibioticsa 370 (76.6) 101 (75.4) 0.679
Previous antifungalsa 67 (13.9) 33 (24.8) 0.002
Previous azole therapy (3 days) a 47 (9.7) 31 (23.1) <0.001
Severity, n (%)
Septic shock 67 (13.9) 27 (20.1) 0.074
Source of infection, n (%)
Primary 268 (55.5) 74 (55.2) 0.957
Catheter-related 168 (34.8) 38 (28.4) 0.163
Urological 27 (5.6) 11 (8.2) 0.265
Abdominal 17 (3.5) 8 (6) 0.203
Other 3 (0.6) 3 (2.2) 0.120
Microbiology
Candida species, n (%)b
C. albicans 288 (58.3) 3 (2.2) <0.001
C. parapsilosis 130 (26.3) 6 (4.57) <0.001
C. glabrata 0 97 (72.3) <0.001
C. tropicalis 50 (10.1) 2 (1.5) <0.001
C. krusei 0 14 (10.4) <0.001
C. guilliermondii 0 9 (6.7) <0.001
Other 26 (5.3) 3 (2.2) 0.067
Abbreviations: Flu-NS, isolates non-susceptible to ﬂuconazole (i.e. those with an
MIC 4 mg/L plus C. krusei, C. glabrata and C. guilliermondii, regardless of their MIC
value); Flu-S, isolates fully susceptible to ﬂuconazole (i.e. those with an MIC <4 mg/
L).
aWithin the preceding month.
bEleven cases of mixed candidaemia.
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and InResults from the multivariate analysis were used to develop
the clinical Flu-NS prediction score. According to the regres-
sion coefﬁcients, we assigned 2 points to HPU and 1 point to
each of the other independent parameters. We also added 1
point for patients with septic shock at presentation. The
application of the score to patients enabled us to categorize
subjects into six different classes: 269 (43.6%) had 0 points, 72
(11.7%) had 1 point, 172 (27.9%) had 2 points, 85 (13.8%) had 3
points, 17 (2.8%) had 4 points and 2 (0.3%) had 5 points. The
incidence of Flu-NS by the CLSI reference procedure in these
groups was 7.1%, 6.9%, 33.7%, 45.9%, 64.7%, and 100%,
respectively. The ROC curve for the Flu-NS prediction score
showed an accuracy measured by the AUC of 0.76 (0.72–0.81)
(Fig. 1, curve A). When applied exclusively to the 26 neu-
tropenic patients of this cohort, the Flu-NS score conserved its
performance (ROC curve AUC 0.79 (0.59–0.98)). Diagnostic
sensitivity, speciﬁcity and predictive values according to
different cut-off values in the derivation cohort are shown in
Table 4. A cut-off point of 2 for the Flu-NS score had a
sensitivity of 82.1%, a speciﬁcity of 65.6% and a negative pre-
dictive value of 93% (Table 4). Using the MIC cut-off value
obtained by the EUCAST procedure to classify episodes as Flu-
NS in the same cohort, the score retained an AUC of 0.79 (95%
CI 0.76–0.83) (Fig. 1, curve B). The application of the score
when the MIC values were obtained by the EUCAST procedure
enabled us to categorize subjects into six different classes: 221
(35.9%) had 0 points, 64 (10.4%) had 1 point, 218 (35.4%) had 2
points, 93 (15.1%) had 3 points, 18 (2.9%) had 4 points and 2
(0.3%) had 5 points. The incidence of Flu-NS in these groups
was 2.7%, 3.1%, 36.2%, 46.2%, 66.7% and 100%, respectively.
External validation
The application of the score to patients in the validation cohort
enabled us to categorize them into six different classes: 96
(32.3%) had 0 points, 28 (9.4%) had 1 point, 109 (36.7%) had 2
points, 47 (15.8%) had 3 points, 15 (5%) had 4 points and 2
(0.7%) had 5 points. The incidences of Flu-NS in the validation
cohort ranged from 6% for patients without risk factors to 64%fectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 684.e1–684.e9
FIG. 1. Receiver operating characteristics (ROC) curve for the Flu-NS score in three cohorts: (a) derivation, (b) EUCAST internal validation and (c)
external validation. Abbreviations: EUCAST, European Committee on Antimicrobial Susceptibility Testing; Flu-NS, isolates non-susceptible to ﬂu-
conazole (i.e. those with an MIC 4 mg/L plus Candida krusei, Candida glabrata and Candida guilliermondii, regardless of their MIC value).
684.e5 Clinical Microbiology and Infection, Volume 21 Number 7, July 2015 CMIfor subjects with 4 or more points on the score, with an AUC
of 0.72 (95% CI 0.65–0.79) (Fig. 1, curve C). When applied
exclusively to the 30 neutropenic patients of this cohort, the
Flu-NS score conserved its performance (ROC curve AUC
0.71 (0.51–0.90)). Diagnostic sensitivity, speciﬁcity and pre-
dictive values according to different cut-off values in the vali-
dation cohort are also shown in Table 4.DiscussionIn the present study, we have created and validated a simple
score that can estimate the risk of Flu-NS candidaemia using
readily available clinical parameters at the bedside. Speciﬁcally,
the presence of hospitalization to an HPU before trans-
plantation, and at least 3 days of prior azole therapy as inde-
pendent predictors of Flu-NS by multivariate analysis allowed
us to create a valid prediction score. The absence of any of
these predictive factors decreased the risk of Flu-NS candi-
daemia substantially, supporting the empirical use of ﬂuconazole
as the ﬁrst antifungal agent. To our knowledge, this is the ﬁrst
investigation to have developed a clinically relevant tool to
guide empirical antifungal therapy in this setting. Interestingly,TABLE 4. Receiver operating characteristic curve cut-off values for
Cut-off point
Derivation cohort EUCAST inter
Sn Sp NPV PPV Sn Sp
‡1 85.8 51.8 92.9 33 95.8 45.6
‡2 82.1 65.6 93 39.9 94.4 58.7
‡3 38.8 89.2 84 50 39.6 88.1
‡4 9.7 98.8 79.7 68.4 9.7 98.7
5 1.5 100 78.5 100 1.4 100
Abbreviations: EUCAST, European Committee on Antimicrobial Susceptibility Testing; NPV
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectthe score appears to retain its applicability when using the
EUCAST breakpoints.
Many previous studies have attempted to identify risk factors
associated with azole resistance. Some have analysed non-
albicans candidaemia as a surrogate marker of azole resistance
and found risk factors such as chemotherapy [19], solid tumour
[20] or previous surgery [21]. Other works with microbiological
conﬁrmation of resistance have described gastrointestinal sur-
gery [22] or the cumulative length of hospitalization [23] as being
relevant; however, these were single-centre studies limited to
oncological or critically ill surgical patients, respectively. Another
prospective study reported that neutropenia, chronic renal dis-
ease and previous ﬂuconazole exposure were independently
associated with such strains [24]. Previous azole therapy was
also found to be a risk factor in other works [25,26], all those
based on the old CLSI breakpoints. Furthermore, we found that
both prior antifungal therapy and its duration were independent
risk factors, a fact already demonstrated by other authors who
observed a dose-dependent relationship between ﬂuconazole
consumption and breakthrough azole-resistant candidaemia [27].
This evidence supports the guideline recommendation of
avoiding ﬂuconazole as the initial empiric therapy in those pa-
tients with previous exposure [3].the derivation and validation cohorts
nal validation External validation cohort
NPV PPV Sn Sp NPV PPV
97.3 35 87.7 39.6 93.1 25.6
97.1 41 84.2 49.6 92.9 28.4
82.7 50.4 42.1 84.4 85.8 39.3
78.2 70 17.5 97.9 83.2 66.7
76.9 100 1.8 100 80.9 100
, negative predictive value; PPV, positive predictive value; Sn, sensitivity; Sp, speciﬁcity.
ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 684.e1–684.e9
CMI Cuervo et al. Predicting ﬂuconazole non-susceptible candidaemia 684.e6In the present study, we stressed the importance of local
epidemiology in the pre-test probability of developing Flu-NS
candidaemia. We found that being hospitalized in a unit with
a Flu-NS candidaemia prevalence of 15% had the highest
weighting as a predictor in our score. In fact, data from the
CANDIPOP survey showed a great difference in the prevalence
of Flu-NS strains among the different participating cities [13].
This is clearly evident when we compare countries of northern
Europe with Latin-America [28,29], or wider comparisons as
the SENTRY Antimicrobial Surveillance Program [30]. Our
results highlight the importance of local surveillance studies.
Our multivariate analysis found that transplantation recipient
status was an independent predictor of Flu-NS candidaemia.
Previous reports on haematological neutropenic patients
receiving stem cell transplantation found similar results [31,32].
Nevertheless, information concerning solid organ trans-
plantation is conﬂicting, with some authors reporting greater
azole resistance [33] and others failing to report this association
[34]. However, these ﬁndings are difﬁcult to compare because
of differences in the design, deﬁnitions and populations used in
those studies.
To date, no evidence supports the argument that azole-
resistant strains are associated with a greater incidence of
septic shock. Despite this, the fungicidal activity of echino-
candins against most Candida species is argued to be a reason
for offering these drugs to unstable patients [3]. Further studies
are needed to validate this hypothesis. However, the addition of
septic shock to our clinical prediction score provides a safety
factor for clinicians, who usually prefer broad-spectrum
coverage in critically ill patients.
Our clinical prediction score faces physicians with quite
different settings. On the one hand, there is a patient subgroup
with low risk (score <1) in whom empirical ﬂuconazole appears
to be a safe initial treatment. On the other hand, there is a
patient subgroup with several risk factors (score 2) and a high
probability of Flu-NS candidaemia. Together with critically ill
patients, those patients warrant broad-spectrum therapy, with
ﬂuconazole reserved as a step-down option. Finally, for those
patients with 3 or more points on the Flu-NS score, the use of
an echinocandin should be mandatory because of the high risk
of Flu-NS isolates. To note, echinocandin-resistance (though
not common) may be observed in some Flu-NS isolates.
The strengths of the current study include the prospective
nature of the derivation cohort, the large number of consec-
utive patients evaluated, the comprehensive data collection, and
the multicentre design. Moreover, it is also important that
validation be provided in an international cohort, including
patients from different geographic areas. Nevertheless, the
predictive power of the score needs to be conﬁrmed in even
more diverse clinical settings to ensure its wider validity andClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Inreliability. The limitations of the present study include differ-
ences in MIC determination techniques between the derivation
and validation cohorts. As the MIC breakpoints are method-
speciﬁc, using the CLSI breakpoints for interpretation of the
MICs generated by Sensititre YeastOne or Etest in the valida-
tion cohort may have led to discordant results in a number of
isolates. Second, it is true that our score mostly identiﬁed Flu-
NS strains corresponding to non-albicans species, with primary
resistance or dose-dependent susceptibility to ﬂuconazole.
However, the Flu-NS score was also useful for patients with
isolates with acquired resistance to ﬂuconazole (11 isolates:
three C. albicans, six C. parapsilosis and two C. tropicalis). Among
them, more than 90% (10/11) had 2 points and more than
63% (7/11) had 3 points in the score. Third, it is certainly
possible that the rapid evolution of molecular diagnostic
methods [35] may lead to clinical tools such as this becoming
redundant; however, the availability of such techniques will
remain restricted in resource-limited settings. Finally, a major
drawback is in the nature of a prediction score that aims to
simplify a complex clinical situation. We stress that such a tool
should support, but never replace, clinical judgement.
In summary, our easy to use, simple Flu-NS prediction score
can estimate the risk of Flu-NS candidaemia using readily
available clinical parameters at the bedside. This gives physicians
a validated and reliable tool to enable the rational and safe
choice of an initial antifungal agent in the management of can-
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